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Abstract
Polymeric particles and liposomes are efficient tools to overcome the low immunogenicity 
of subunit vaccines. The aim of the present study was formulation and optimization of a new 
cationic lipid-modified PLGA nanoparticles (NPs) as a delivery system for Mycobacterium 
tuberculosis HspX/EsxS fusion protein. The cationic lipid-modified PLGA NPs containing 
HspX/EsxS fusion protein were prepared using a modiﬁed double emulsion solvent evaporation 
method. Scanning electron microscopy and dynamic light scattering (DLS) tools were used to 
determine physical properties of hybrid NPs. A multi-level full factorial design was used to 
evaluate the influence of two factors of PLGA:DDA weight ratio (w/w) and PVA concentration 
(%) on size, surface charge, polydispersity index, encapsulation efficiency and yield. Finally, 
the optimal formulation was achieved based on desired responses. Mathematical models 
were obtained to indicate the relation between the studied factors and responses. The DDA 
concentration showed an increasing effect on surface charge and also a decreasing effect on 
particle size, encapsulation efficiency and yield. Higher amounts of DDA increased surface 
charge of NPs; however, the size, encapsulation efficiency and yield were decreased. The 
influence of various concentrations of PVA on different physical characteristics of PLGA:DDA 
hybrid NPs was variable. The optimal formulation consisted of 0.91 (55:5, w/w) weight ratio 
of PLGA:DDA and 0.5% PVA. The hybrid NPs showed acceptable particle size distribution, 
strong positive surface charge, prolonged antigen release and good encapsulation efficiency in 
comparison to PLGA alone. However, further preclinical and clinical studies are needed. 
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Introduction
Mycobacterium tuberculosis (M. 
tuberculosis), the causative agent of tuberculosis 
(TB), is one of the significant issues in global 
public health, due to more than two million 
deaths annually (1). Currently, the only efficient 
way for global TB control is BCG (M. bovis 
Bacillus Calmette-Guérin) vaccination. 
However, its protective efficacy in all parts 
of the worlds is not yet fully good (0 to 80%) 
(2). Therefore, it is an urgent need to improve 
or develop a new TB vaccine. Many attempts 
have been made to establish effective vaccines 
in order for either replacement with BCG, 
such as live recombinant BCG (rBCG) and 
modified non-pathogenic mycobacteria (M. 
vaccae, and M. smegmatis), or booster vaccines 
(either prophylactic or therapeutic), such as 
subunit vaccines, DNA vaccines, viral-vectored 
candidates and inactivated whole cell vaccines 
(2, 3). Among them, subunit vaccines are 
highly regarded. However, these vaccines are 
intrinsically weak immunogens (4). To solve 
this problem, polymeric nanoparticles (NPs), 
especially PLGA (poly (lactide-co-glycolide)) 
and also liposomes have attracted many attentions 
as efficient vaccine delivery platform/adjuvant 
(5-7). Both liposomes and polymeric NPs have 
some common benefits including adjustable 
size, biocompatibility and high encapsulation 
efficiency (8). An important feature of liposomes 
is the ability to encapsulate both hydrophilic 
and hydrophobic materials in their aqueous 
core or between lipid layers, respectively 
(8). PLGA is a non-toxic, biocompatible and 
biodegradable synthetic polymer approved by 
the U.S Food and Drug Administration (FDA) 
for human application and the proteins and 
peptides nanomedicines, etc. (9, 10). It has been 
used to develop the drug delivery and vaccine 
delivery systems due to controlled release 
properties, versatile degradation to completely 
safe materials in-vivo, easy production and 
structural diversity (10). In recent years, various 
studies have demonstrated that the surface of 
PLGA could be coated with cationic lipids such 
as DOTAP, DOPC, and DOPG in order to 
form lipid-polymer complexes, hybrid NPs, 
which can be an excellent TB vaccine delivery 
platform with high rate of antigen encapsulation, 
prolonged release of antigen, good serum 
stability and induced strong immune responses 
(9-12). DDA, dimethyl dioctadecylammonium 
bromide, is a cationic liposome-forming lipid 
classified in quaternary ammonium compounds. 
This synthetic amphiphilic lipid in combination 
with different immunomodulators is well defined 
as an excellent adjuvant in order to promote 
humoral and Th1 type of cell-mediate responses 
(13). The aim of this study was to design a new 
cationic lipid-modified PLGA hybrid NP as an 
excellent delivery system for M. tuberculosis 
HspX/EsxS fusion protein.
Experimental
Materials 
PLGA (Resomer® RG 752 H, poly (D, 
L-lactide-co-glycolide) acid terminated, 
lactide:glycolide 75:25, MW 4,000-15,000), 
PVA (poly (vinyl alcohol), MW 89000 to 98000, 
99% degree of hydrolysis) and DDA were 
purchased from Sigma-Aldrich Chemie GmbH 
(Germany). Dichloromethane at analytical grade 
was obtained from Sigma-Aldrich.
Experimental design
A multi-level full factorial design was used 
to formulate the hybrid NPs by double emulsion 
solvent evaporation method. The effect of two 
parameters of PLGA:DDA weight ratio (w/w) in 
5 levels and PVA concentration (%) in 3 levels, 
as independent variables, were evaluated. The 
design parameters and their levels are shown in 
Table 1. 
Table 1. Factorial design parameters: independent variables and levels.
Independent variables Levels
X1: PLGA:DDA weight ratio (w/w) 30:30 40:20 (0.66) 50:10 (0.83) 55:5 (0.91) 100:0 (1)
X2: PVA concentration (%) 0.5 1 2
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The impact of these parameters on physical 
properties of hybrid NPs such as mean particle 
diameter (Z-average, nm), surface charge (Zeta-
potential, mV), polydispersity index (PDI), 
encapsulation efficiency (%) and yield  (%), as 
dependent variables or responses, were studied 
(Table 1).
Preparation of PLGA:DDA hybrid NPs
Molecular cloning, expression and 
purification of M. tuberculosis HspX/EsxS 
fusion protein was previously performed and 
reported (14). PLGA:DDA hybrid NPs were 
prepared using a modiﬁed w/o/w double 
emulsion solvent evaporation method (9). 
Brieﬂy, as shown in Table 2, various weight 
ratios of PLGA and DDA, at a final concentration 
of 60 mg/mL, were weighted and dissolved 
in 600 µL dichloromethane as organic phase. 
Hundred twenty µL of a 1 mg/mL HspX/EsxS 
fusion protein solution in ultrapure water was 
added to organic phase. The first sonication 
was performed by an ultrasonic homogenizer 
(Hielscher – Ultrasound Technology, Germany) 
for 30 s to establish water-in-oil (w1-o) emulsion. 
To obtain water-in-oil-in-water (w1-o-w2) 
emulsion, 4 mL of 0.5, 1, and 2% (w/v) of PVA 
was added to w1-o emulsion and then second 
sonication was performed for 60 s. To complete 
evaporation of dichloromethane, the suspension 
was slowly added to 20 mL of 0.3% (w/v) of 
PVA and stirred for 24 h. Finally, the suspension 
was centrifuged at 18000 g, 4 °C for 12 min and 
the pellet was washed three times with 10 mL of 
ultrapure water. NPs were re-suspended in 1 mL 
ultrapure water, freeze-dried and stored at 4 °C 
for later use.
Evaluation of physical characteristics of 
PLGA:DDA hybrid NPs
Complete physical characteristics of hybrid 
NPs including Z-average (nm), Zeta-potential 
(mV) and PDI were determined by dynamic 
light scattering (Zetasizer Nano, Malvern, UK). 
For above purposes, 1 mg of each freeze-dried 
NP formulation was re-suspended in 1 mL of 
ultrapure water and sonicated in an ultrasonic 
bath for 2 min. The scanning electron microscopy 
(SEM) was used to evaluate the morphology 
of protein-loaded hybrid NPs. NPs yield was 
determined as the percentage of residual NPs to 
the theoretical weight after freeze-drying.
Determination of HspX/EsxS encapsulation 
efficiency
In order to determine the encapsulation 
efﬁciency of HspX/EsxS fusion protein, this 
protein was first radiolabelled by an iodination 
technique (15). Briefly, 10 µg of purified 
HspX/EsxS protein was diluted with 45 µL of 
phosphate buffer (0.5 M, pH 7.5) and added 
to 10 µL of predetermined activity of 125I (200 
µCi). Then, 20 µL of chloramine-T (2 mg/mL, 
pH 7.5), as a powerful oxidizing agent, and 50 
µL of sodium metabisulfite (Na2S2O5) (4 mg/
mL, pH 7.5), as a reducing agent, were added 
and the mixture stirred for 30 s and 60 s at room 
temperature, respectively. The reaction mixture 
was further diluted with 100 µL of potassium 
iodide (KI) (10 mg/mL, pH 7.5) and stirred for 
2 min and then purified by the gel filtration 
chromatography column. Pooled protein aliquots 
were used for preparation of PLGA:DDA hybrid 
NPs to determine encapsulation efﬁciency. 
Protein encapsulation efﬁciency was determined 
by Gamma counter (Packard Instruments 
Company Inc., IL, USA) using the following 
equation: Protein encapsulation efﬁciency 
(%) = Gamma radiation emitted from pellet/
Total gamma radiation × 100 (16). Thin layer 
chromatography (TLC) technique using silica 
gel, as the stationary phase, and normal saline, 
as the mobile phase, Were used to evaluate 
radiolabelling efficiency and physical stability 
of HspX/EsxS protein-NP complex in human 
serum and PBS medium.
In-vitro HspX/EsxS protein release profile 
To evaluate the release proﬁle, 125I-labelled 
HspX/EsxS protein was encapsulated with 
PLGA:DDA hybrid NPs. NPs were suspended 
in a 15 mL release medium (PBS, pH 7.4) and 
incubated at 37 °C under constant agitation. At 
certain time points, 1 mL samples of medium 
were taken and centrifuged at 10000 g for 15 
min. Gamma radiation emitted from supernatant 
was counted and recorded. Followed equation 
was used to calculate the protein release proﬁle, 
HspX/EsxS release percent = Gamma radiation 
emitted from supernatant/Total gamma radiation 
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Table 2. Physical characteristics of PLGA:DDA hybrid NPs.
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× 100. Finally, 1 mL of fresh buffer was added 
to release medium (16).
Data analysis
By using a polynomial equation: Y = a1X1 + 
a2X2 + a3X12 + a4X22 + a5X1X2, the influence of 
independent variables on dependent variables 
were evaluated. Statistical analysis of data 
and the modeling were performed through 
the SPSS software (version 16). Statgraphics 
Centurion software (version 16) was used to 
draw the surface plot and the contour plot. 
All experiments were repeated for 3 times 
and the results expressed as mean ± SD and 
if p < 0.05, it was considered as statistically 
significant.
Results and Discussion
Effect of formulation factors on particle size 
distribution
PLGA:DDA hybrid NPs were produced by 
the modiﬁed w/o/w double emulsion solvent 
evaporation method with different levels of two 
parameters, PLGA:DDA weight ratio (w/w) and 
PVA concentration (%). Physical characteristics 
of PLGA:DDA hybrid NPs including particle 
size, Zeta-potential, PDI, encapsulation 
efficiency, yield and composition of different 
formulation were listed in Table 2. A key factor 
for the adjuvant activity of PLGA NPs is their 
particle size. Particle sizes in the range of 300 
to 600 nm are capable to enhance type 1 (Th1) 
immune responses due to more efficient uptake 
by antigen-presenting cells (APCs), which is 
necessary for effective TB immunity, while in 
the range of 2-8 µm, they induce Th2 responses 
(17). Except for 0.5% PVA, there is a decrease 
in the size distribution from 360.1 ± 31.3 nm at 
0% DDA (w/w) to 200.7 ± 26.5 nm at 50% DDA 
(w/w) for 1% PVA concentration as well as from 
319.2 ± 4.3 nm to 213.2 ± 16.1 nm for 2% PVA 
concentration (Table 2). 
The correlation between Z-average 
(nm), PLGA:DDA weight ratio and different 
concentrations of PVA were clearly shown in 
the three dimensional display of surface plot and 
contour plot (Figure 1). An obvious positive effect 
of the DDA weight ratio to total concentration of 
hybrid NPs was observed for the particle size. 
Based on Figure 1, a significant concentration-
dependent decrease in the particle size (nm) 
was observed by increasing the concentration 
of cationic lipid DDA from 0% to 50% (w/w) 
(p < 0.05). Similar results in agreement with 
this study have been shown by using of other 
cationic compounds like DOTAP and PEI to 
modify the PLGA NPs (9). However, Kirby 
and colleagues reported that the addition of the 
DDA to the NPs formulation led to increase 
in the size due to aggregation (16). Increasing 
PVA concentration from 0.5% to 2% had no 
effect on the mean particle size (Figure 1). The 
obtained model for particle size and the results 
of regression analysis are as follow:
Effect of formulation factors on surface 
charge
It has been established that increase in 
surface charge of NPs (Zeta-potential, mV) has 
a positive impact on induction of strong immune 
responses (16). Furthermore, positively charged 
NPs show more interaction and cellular uptake 
and also allow for more antigen adsorption (17, 
18). Based on Hu and colleagues study, PLGA 
NPs modified with cationic lipid showed more 
stability, more prolonged in-vitro antigen release 
and better uptake by dendritic cells (DCs) (8). As 
compared with negatively charged and neutral 
particles, positively charged particles show 
more interaction and uptake into the cells as well 
as escape from the lysosomes. This is performed 
through the ionic interaction with negatively 
charged cell membranes (18-20). At the present 
study, negatively charged PLGA polymer was 
selected as the backbone of a hybrid NPs and 
their surface were modified with cationic lipid, 
DDA. After addition of DDA, total surface 
charge changed to neutral or positive. 
The impact of PLGA:DDA weight ratio 
(w/w) and PVA concentration (%) on surface 
charge have been shown in Figure 2. By increase 
in DDA weight ratio from 0 to 50% (w/w), Zeta-
potential (mV) showed a nearly same positive 
trend in all three PVA concentrations and surface 
charge of NPs was changed from negative for 
unmodified PLGA NPs to positive for modified 
type (p < 0.05) (Table 2). Positively charged 
DDA electrostatically interacts with negatively 
charged PLGA via its quaternary ammonium 
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compounds and changes physicochemical 
characteristics of hybrid NPs (17). The influence 
of PVA concentration on the surface charge of 
NPs was negligible. 
The obtained model for surface charge and 
the results of regression analysis are given 
below:
Effect of formulation factors on PDI
The polydispersity index (PDI) represents the 
width of the size distribution and is a measure 
for the heterogeneity of particle sizes. The PDI 
values are in the range of 0 to 1. Uniform 
or monodisperse particles show 0 value (10). 
As shown in Figure 3, the influence of DDA 
addition to the formulations was variable in 
the different PVA concentrations. In the case of 
2% PVA concentration, by increasing of DDA 
concentration, more monodisperse NPs was 
obtained and PDI was changed from about 0.4 to 
about 0.1. However, in 0.5% PVA concentration, 
PDI increased from about 0.2 to about 0.3 nm, 
a non-uniform (polydisperse) formulation which 
has an inconsistent size. However, in 1% PVA 
concentration, changes in DDA concentration 
have no effect on PDI. The obtained model 
for PDI and the results of regression are given 
below: 
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Figure 1. Effect of formulation factors on particle size (Z-average); above: 3D 
surface plot, below: contour plot. 
 
 
Z-average (nm): 181.832 + 137.848 X12, R2= 0.348  
 
Model Sum of 
Squares 
df Mean Square F Sig.* 
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*Level of signiﬁcance p< 0.05 
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Figure 1. Effect of formulation factors on particle size (Z-average); above: 3D surface plot, below: contour plot.
Z-average (nm): 181.832 + 137.848 X12, R2= 0.348                (1)
Model Sum of Squares df Mean Square F Sig.*
Regression 61780.614 1 61780.614 22.984 0.001
Residual 115583.514 43 2687.989
Total 177364.128 44
Predictors: (Constant), X1X1
Dependent Variable: Z-average (nm)
*Level of signiﬁcance p< 0.05
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Effect of formulation factors on encapsulation 
efficiency
One of the most important characteristics of 
PLGA NPs as an ideal candidate for the delivery 
of the subunit vaccines is prolonged release 
of encapsulated antigens which is important 
to eliminate or reduce multiple booster doses 
of subunit vaccines (21). Encapsulation of 
the subunit vaccines with NPs could improve 
their in-vitro and in-vivo physical stability and 
prevent from changes in the protein structures 
such as protein denaturation and aggregation as 
well as chemical instability such as hydrolysis, 
oxidation and deamination (21). 
The HspX/EsxS fusion protein was 
encapsulated with PLGA:DDA hybrid NPs 
with varying amounts of DDA. As shown in 
Table 2 and Figure 4, in all formulations, DDA 
has a negative effect on encapsulation rate of 
HspX/EsxS fusion protein. Increase in weight 
ratio of DDA from 0 to 50% (w/w) led to 
a significant decrease in antigen entrapment 
efficiency (p < 0.05). This observation can be 
attributed to more porosity of PLGA:DDA NPs 
with more DDA ratio and resulting leakage 
of encapsulated HspX/EsxS (16). Similar to 
the surface charge response, the influence of 
various PVA concentrations on the encapsulation 
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Figure 2. Effect of formulation factors on Zeta-potential (mV); above: 3D surface 
plot, below: contour plot. 
 
Zeta-potential (mV): -223.506 + 830.920 X1 - 5.790 X2 - 623.854 X12, R2= 0.842 
 
Model Sum of 
Squares 
df Mean Square F Sig.* 
 Regression 26153.888 3 8717.963 72.856 0.0001 
 Residual 4906.054 41 119.660   
 Total 31059.942 44    
Predictors: (Constant), X1X1, X2, X1    
Dependent Variable: Zeta-potential (mV)     
  *Level of signiﬁcance p < 0.05 
(2) 
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Figure 2. Effect of formulation factors on Zeta-potential (mV); above: 3D surface plot, below: contour plot.
Ze a-p tential (mV): -223.506 + 830.920 X1 - 5.790 X2 - 623.854 X12, R2= 0.842       (2)
Model Sum of Squares df Mean Square F Sig.*
Regression 26153.888 3 8717.963 72.856 0.0001
Residual 4906.054 41 119.660
Total 31059.942 44
Predictors: (Constant), X1X1, X2, X1
Dependent Variable: Zeta-potential (mV)
*Level of signiﬁcance p< 0.05
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efficiency was negligible. The obtained model 
for encapsulation efficiency and the results of 
regression are given below:
Effect of formulation factors on NPs yield
The higher production yield of NPs means the 
lower production costs. Therefore, evaluation of 
different factors on NPs production yield is 
essential. As shown in Table 2, in all of PVA 
concentrations, more PLGA:DDA ratios resulted 
higher production yields (23 ± 2.6 to 55.1 ± 2.1 
mg, 27.3 ± 2.5 to 58.4 ± 1 mg and 26 ± 2 to 57 ± 
1 mg at 0.5%, 1% and 2% PVA concentrations, 
respectively). Murakami and colleagues have 
also showed that the appropriate selection of 
organic solvents could optimize the NPs yield 
(22). Here, effects of two formulation factors on 
NPs yield were studied. 
The PVA concentration had no significant 
effect on the yield. However, as shown in Figure 
5, DDA concentration had a negative effect 
on NP yield (p < 0.05). Like encapsulation 
efficiency model, the obtained model for PDI 
was accurate and model equation and the results 
of regression of responses are given below:
Effect of formulation factors on antigen 
release profile
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Figure 3. Effect of formulation factors on polydispersity index; above: 3D surface 
plot, below: contour plot. 
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PDI: 0.398 - 0.175 X1 - 0.110 X2 + 0.128 X1X2, R2= 0.471        (3)
Model Sum of Squares df Mean Square F Sig.*
Regression .170 3 .057 12.178 0.0001
Residual .191 41 .005
Total .361 44
Predictors: (Constant), X1X2, X2, X1
Dependent Variable: PDI
*Level of signiﬁcance p< 0.05
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In-vitro release characteristics of M. 
tuberculosis HspX/EsxS fusion protein from 
various formulations of lipid-modified PLGA 
NPs were studied in a 15 mL release medium 
(PBS, pH 7.4) for 1 month (Figure 6). As shown 
in Figure 6, after 1 day, an initial release with 
less than 20% for 30:30 (w/w) and 40:20 (w/w) 
weight ratios and more than 20% for 50:10 
(w/w) and 55:5 (w/w) weight ratios as well as 
unmodified PLGA NPs was observed. 
The hybrid NPs with 30:30 (w/w) ratio 
displayed the least antigen release rate up to the 
first 3 days, however, from day 3 to 28, 40:20 
(w/w) ratio of the hybrid NPs showed the least 
antigen release rate. In comparison with cationic 
lipid-modified PLGA with a sustained and 
prolonged release profile, unmodified PLGA 
NPs showed the most rapid antigen release.
Morphology of PLGA:DDA hybrid NPs
The morphology of hybrid NPs was 
evaluated by scanning electron microscopy 
(SEM) (MIRA3 LM, Czech Republic). For this 
purpose, an amount of freeze-dried NPs were 
prepared on aluminum stubs using double-sided 
carbon tape and then by using sputter coater 
(Quorum Technologies Ltd, UK) and under 
Argon atmosphere, a thin film of Gold particles 
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Figure 4. Effect of formulation factors on encapsulation efficiency (%); above: 
3D surface plot, below: contour plot. 
 
Encapsulation efficiency (%): 101.362 – 367.654 X1 + 352.825 X12 + 6.068 X1X2, 
R2= 0.977 
Model Sum of Squares df Mean Square F Sig.* 
 Regression 45847.018 3 15282.339 584.214 0.001 
Residual 1072.511 41 26.159   
Total 46919.530 44    
Predictors: (Constant), X1X2, X1X1, X1    
Dependent Variable: Encapsulation Efficiency 
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Figure 4. Effect of formulation factors on encapsulation efficiency (%); above: 3D surface plot, below: contour plot.
Encapsulation efficiency (%): 101.362 – 367.654 X1 + 352.825 X12 + 6.068 X1X2, R2= 0.977       (4)
Model Sum of Squares df Mean Square F Sig.*
Regression 45847.018 3 15282.339 584.214 0.001
Residual 1072.511 41 26.159
Total 46919.530 44
Predictors: (Constant), X1X2, X1X1, X1
Dependent Variable: Encapsulation Efficiency (%)
*Level of signiﬁcance p< 0.05
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Figure 5. Effect of formulation factors on yield (%); above: 3D surface plot, 
below: contour plot. 
 
Yield (%): 24.634 - 55.175 X1 + 16.380 X2 + 79.903 X12 - 5.568 X22 - 1.592 X1X2, 
R2= 0.977 
 
Model Sum of 
Squares 
df Mean Square F Sig.* 
  Regression  5767.418 5 1153.484 338.189 0.001 
Residual 133.020 39 3.411   
Total 5900.438 44    
1X, 2X, 2X2X, 1X1X, 2X1XPredictors: (Constant),    
Dependent Variable: Yield (%)     
 *Level of signiﬁcance p < 0.05 
(5) 
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Figur  5. Effect of formulation factors on yield (%); above: 3D surface plot, below: contour plot.
Yield (%): 24.634 - 55.175 X1 + 16.380 X2 + 79.903 X12 - 5.568 X22 - 1.592 X1X2, R2= 0.977        (5)
Model Sum of Squares df Mean Square F Sig.*
Regression 5767.418 5 1153.484 338.189 0.001
Residual 13 .020 39 3.411
Total 5900.438 44
Predictors: (Constant), X1X2, X1X1, X2X2, X2, X1
Dependent Variable: Yield (%)
*Level of signiﬁcance p< 0.05
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Effect of formulation factors on antigen release profile 
In-vitro release characteristics of M. tuberculosis HspX/EsxS fusion protein from 
various formulations of lipid-modified PLGA NPs were studied in a 15 mL 
release medium (PBS, pH 7.4) for 1 month (Figure 6). As shown in Figure 6, after 
1 day, an initial release with less than 20% for 30:30 (w/w) and 40:20 (w/w) 
weight ratios and more than 20% for 50:10 (w/w) and 55:5 (w/w) weight ratios as 
well as unmodified PLGA NPs was observed. The hybrid NPs with 30:30 (w/w) 
ratio displayed the least antigen release rate up to the first 3 days, however, from 
day 3 to 28, 40:20 (w/w) ratio of the hybrid NPs showed the least antigen release 
rate. In comparison with cationic lipid-modified PLGA with a sustained and 
prolonged release profile, unmodified PLGA NPs showed the most rapid antigen 
release. 
 
 
Figure 6. Cumulative release of HspX/EsxS fusion protein from different formulation of 
PLGA:DDA hybrid NPs in PBS (pH 7.4) at 37 °C. All data presented as means ± SD (n = 3). 
 
Morphology of PLGA:DDA hybrid NPs 
The morphology of hybrid NPs was evaluated by scanning electron microscopy 
(SEM) (MIRA3 LM, Czech Republic). For this purpose, an amount of freeze-
Figure 6. Cumulative release of HspX/EsxS fusion protein from different formulation of PLGA:DDA hybrid NPs in PBS (pH 7.4) at 37 
°C. All data presented as means ± SD (n = 3).
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dried NPs were prepared on aluminum stubs using double-sided carbon tape and 
then by using sputter coater (Quorum Technologies Ltd, UK) and under Argon 
atmosphere, a thin film of Gold particles were sputter coated on NPs. As shown in 
Figure 7, increasing the amount of DDA leads to the agglomeration and 
aggregation of particles and makes the irregular shapes. In blank PLGA and also 
NPs with low concentration of DDA, the shape of NPs was spherical and with 
smooth surface. However, it was irregular in higher concentration of DDA. There 
was a difference between the size distributions measured by SEM and DLS. 
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Figure 7. Scanning electron micrograph of surface of PLGA:DDA hybrid NPs containing 30 mg 
PLGA and 30 mg DDA (A), 40 mg PLGA and 20 mg DDA (B), 50 mg PLGA and 10 mg DDA 
(C), 55 mg PLGA and 5 mg DDA (D) and 60 mg PLGA and 0 mg DDA (E). (Scale bar represents 
1 µm). 
 
Optimization of NPs formulation 
To identify the optimal formulation, following criteria as the desired range of each 
parameter was selected: the Zeta-potential > +10 mV, yield > 45% and 
encapsulation efficiency > 50%. A graphical approach was used by superimposing 
the contour plots of mentioned responses to obtain the optimum region and an 
optimum point for hybrid NPs formulation. As shown in Figure 8, the optimal 
formulation was formulation No. 4 which consisted of 91% or 55:5 (w/w) weight 
ratio of PLGA:DDA and 0.5% PVA.  
 
Figure 7. Scanning electron micrograph of surface of PLGA:DDA hybrid NPs containing 30 mg PLGA and 30 mg DDA (A), 40 mg 
PLGA and 20 mg DDA (B), 50 mg PLGA and 10 mg DDA (C), 55 mg PLGA and 5 mg DDA (D) and 60 mg PLGA and 0 mg DDA (E). 
(Scale bar represents 1 µm).
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were sputter coated on NPs. As shown in Figure 
7, increasing the amount of DDA leads to the 
agglomeration and aggregation of particles and 
makes the irregular shapes. In blank PLGA and 
also NPs with low concentration of DDA, the 
shape of NPs was spherical and with smooth 
surface. However, it was irregular in higher 
concentration of DDA. There was a difference 
between the size distributions measured by SEM 
and DLS.
Optimization of NPs formulation
To identify the optimal formulation, 
following criteria as the desired range of each 
parameter was selected: Zeta-potential > +10 
mV, yield > 45% and encapsulation efficiency 
> 50%. A graphical approach was used by 
superimposing the contour plots of mentioned 
responses to obtain the optimum region and 
an optimum point for hybrid NPs formulation. 
As shown in Figure 8, the optimal formulation 
was formulation No. 4 which consisted of 91% 
or 55:5 (w/w) weight ratio of PLGA:DDA and 
0.5% PVA. 
Conclusion
Production of a new cationic lipid-modified 
PLGA NP as delivery system for M. tuberculosis 
HspX/EsxS fusion protein was reported. Hybrid 
NPs showed desirable particle size distribution 
and strong positive surface charge, due to 
adding DDA, which could be adsorbed by APCs 
more efficiently and show a strong induction 
of Th1 type of cell-mediate responses. Hybrid 
NPs showed also prolonged antigen release and 
acceptable encapsulation efficiency which can 
be use be used to eliminate or reduce multiple 
booster doses of future subunit vaccines. We 
are optimistic about results obtained in order to 
introduction of PLGA:DDA NPs as a potential 
antigen delivery system. However, to confirm 
these claims and whether the vaccine can induce 
innate and adaptive immune responses after 
challenge and reduce the bacterial load and 
bacterial growth in early TB exposed individuals, 
further preclinical and clinical studies are 
needed.
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Figure 8. Display of superimposed contour plot to identify the optimal 
formulation; Run4 is selected as an optimum point. 
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